ArticleFrontiers in oncology2025
Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Advancements in intratumoral therapies for liver tumors.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Direct tumoral needle injection of nelitolimod, also known as SD-101, has been evaluated in patients with superficial malignancies, including cutaneous melanoma, with encouraging outcomes. Direct intra-tumoral injections may not be suitable for primary and metastatic liver tumors due to the number and size of the lesions, and the location of target immune cells in the peri-tumoral parenchyma. Conventional systemic infusion may be inadequate due to high intra-tumoral pressure and distribution of the therapeutic in large quantities to non-target tissue. Previous clinical and preclinical reports suggest that nelitolimod favorably reprograms the tumor microenvironment to limit myeloid-induced immunosuppression and promote anti-tumor immunity. The present study was undertaken to further explore the contribution of pressure-enabled drug delivery (PEDD) to the immune and clinical effects of nelitolimod in intrahepatic malignancy. Methods: Transgenic pigs (oncopigs) with liver tumors received intra-arterial infusions of fluorescently labeled ODN2395 or nelitolimod either via PEDD with a specialized infusion device or with conventional microcatheter delivery in both lobar and selective infusions. Near-infrared imaging assessed tissue distribution. The murine liver metastasis (LM) model was developed by injecting MC38-Luc cells into the C57/BL6 spleen and treating with fluorescently labeled nelitolimod (30µg/mouse). Tumor burden was monitored by an Results: Our results demonstrate that PEDD enhanced the intravascular infusion of nelitolimod into the liver tumor and peri-tumoral tissue. PEDD resulted in a significant increase in distribution and signal intensity (a surrogate for concentration) in target tissue compared to needle injection or a standard catheter in the oncopig model. PEDD was also modeled in the murine setting with a pressure-controlled infusion system. Single treatment of nelitolimod via PEDD, significantly reduced tumor progression as compared to systemic administration. PEDD of nelitolimod significantly reduced immunosuppressive MDSCs and an increase in cytotoxic CD8 + T cells within the LM. In conclusion, use of PEDD enhanced targeted therapeutic delivery in swine liver tumors and reduced tumor progression by promoting anti-tumor immunity in murine LM in association with suppressive myeloid cell elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.